LYPSAGEMS - Business-News-Today.com

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Platinum Equity to acquire Energy Distribution Partners after 45 acquisitions and threefold EBITDA growth

Infographic showing Senores Pharmaceuticals Limited’s ₹43 crore manufacturing expansion in India and the United States, nearly 25% quarterly revenue growth, improved operating margins and a 14.4% share-price decline over two trading sessions.

Senores Pharmaceuticals (SENORES) targets 3.2bn annual manufacturing units, yet 50% to 70% utilisation raises a bigger question

People Inc added 320 employees this year. Why is it still cutting 195 jobs?

Infographic showing Aspen Neuroscience pricing its Nasdaq IPO at $15 per share, highlighting sasineprocel’s planned move into Phase 3 testing for Parkinson’s disease, operating runway into the second half of 2028 and the likelihood of additional capital needs.

Aspen Neuroscience (ASPE) prices $140.6m IPO at $15 as Parkinson’s therapy enters pivotal development phase

Read More

Retail Industry News

Aurus Gem is back in profit, but is the LYPSAGEMS turnaround still too fragile?

Aurus Gem returned to FY26 profit, but revenue weakness and stock pressure remain key risks. Find out what LYPSAGEMS investors should watch.

May 30, 2026

web analytics